Synaptogenix Inc (SNPX)

[runncoach]

Thanks Vivid.
I remember 5 or 6 years ago talking withJeffrey Benision,the IR guy at the time (very good I might add) and asking why don't we run a separate trial on APOE4 carriers because of the tremendous amount of evidence for that specific issue. He responded that if the drug works for all patients as the theory suggested, then no need to spend that money. Certainly made sense and lets hope still true. This presentation is certainly something different that what we've recently witnessed these last couple years. Same with the VEGF and better arterial blood flow that was peer reviewed a couple months ago.

Also keep in mind some of our competitors' drugs have shown ZERO benefit to APOE4 carriers.